Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting

Introduction Increasingly in pharmacoepidemiology, linking is required to enrich analytic data to more accurately define study populations, enable adjustment for confounding, and improve capture of health outcomes. When creating such novel linked datasets, researchers should consider their suitabil...

Full description

Bibliographic Details
Main Authors: Nicole Pratt, Danielle Chun, Kourtney Davis, Brad Hammill, Christian Hampp, Christina Mack, Anne-Marie Meyer, Sudha Raman, Donna Rivera, Soko Setoguchi, Til Stürmer, Jennifer Lund
Format: Article
Language:English
Published: Swansea University 2020-12-01
Series:International Journal of Population Data Science
Online Access:https://ijpds.org/article/view/1572
id doaj-bf3b26a56c9548bd89c934a4b901f0ba
record_format Article
spelling doaj-bf3b26a56c9548bd89c934a4b901f0ba2021-02-10T16:42:15ZengSwansea UniversityInternational Journal of Population Data Science2399-49082020-12-015510.23889/ijpds.v5i5.1572Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent ReportingNicole Pratt0Danielle Chun1Kourtney Davis2Brad Hammill3Christian Hampp4Christina Mack5Anne-Marie Meyer6Sudha Raman7Donna Rivera8Soko Setoguchi9Til Stürmer10Jennifer Lund11University of South Australia, on behalf of the International Society of Pharmacoepidemiology Working Group on the feasibility, evaluation and reporting of data-linkage studies in pharmacoepidemiologyUniversity of North CarolinaGlobal Epidemiology, Janssen R&D, Titusville, NJ and University of North CarolinaDuke UniversityU.S. Food and Drug AdministrationReal-World and Analytic Solutions, IQVIA,Research Triangle Park, Durham, NC, USA and University of North CarolinaReal World Data Collaborations, Personalized Health Care (PHC), F. Hoffmann-La RocheDuke University, North CarolinaNational Cancer Institute Rutgers UniversityUniversity of North CarolinaUniversity of North Carolina Introduction Increasingly in pharmacoepidemiology, linking is required to enrich analytic data to more accurately define study populations, enable adjustment for confounding, and improve capture of health outcomes. When creating such novel linked datasets, researchers should consider their suitability to meet research objectives, assess source data completeness and population coverage, and ensure well-defined data governance standards and protections exist. Additionally, while the RECORD-PE guidelines assist in the reporting of studies using observational health data specific to pharmacoepidemiology, they do not address the unique requirements for transparent evaluation and reporting of the data linkage process. Objectives and Approach We aimed to 1) provide guidance on data linkage appropriateness and feasibility to plan purposeful and sustainable new linkages that advance pharmacoepidemiological research and 2) generate a checklist with specific recommendations to assist researchers in providing clear and transparent assessment of the linkage process. To develop these guidelines, a working group comprised of members of the International Society of harmacoepidemiology was formed. Recommendations were open for comment by Society members and endorsed by the Society. Results Guidance for feasibility assessment was categorized into five domains: (1) research objectives and justification; (2) data quality and completeness; (3) the linkage process; (4) data ownership and governance; and (5) overall value added by linkage. A checklist for evaluation and reporting of data-linkage processes covered five domains including; (1) data sources; (2) linkage variables; (3) linkage methods; (4) linkage results; and (5) linkage evaluation, including validation and verification of the resulting linked data. Conclusion/Implications Our guidelines for data linkage feasibility assessment and reporting can be used to inform the design of sustainable linked data resources and for transparent communication of linkage processes. Together, these guidelines will help various stakeholders to critically assess the potential for bias in research based on linked data and help generate actionable evidence. https://ijpds.org/article/view/1572
collection DOAJ
language English
format Article
sources DOAJ
author Nicole Pratt
Danielle Chun
Kourtney Davis
Brad Hammill
Christian Hampp
Christina Mack
Anne-Marie Meyer
Sudha Raman
Donna Rivera
Soko Setoguchi
Til Stürmer
Jennifer Lund
spellingShingle Nicole Pratt
Danielle Chun
Kourtney Davis
Brad Hammill
Christian Hampp
Christina Mack
Anne-Marie Meyer
Sudha Raman
Donna Rivera
Soko Setoguchi
Til Stürmer
Jennifer Lund
Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting
International Journal of Population Data Science
author_facet Nicole Pratt
Danielle Chun
Kourtney Davis
Brad Hammill
Christian Hampp
Christina Mack
Anne-Marie Meyer
Sudha Raman
Donna Rivera
Soko Setoguchi
Til Stürmer
Jennifer Lund
author_sort Nicole Pratt
title Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting
title_short Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting
title_full Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting
title_fullStr Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting
title_full_unstemmed Guidelines for Data Linkage in Pharmacoepidemiology: Assessing Feasibility, Evaluating Quality and Transparent Reporting
title_sort guidelines for data linkage in pharmacoepidemiology: assessing feasibility, evaluating quality and transparent reporting
publisher Swansea University
series International Journal of Population Data Science
issn 2399-4908
publishDate 2020-12-01
description Introduction Increasingly in pharmacoepidemiology, linking is required to enrich analytic data to more accurately define study populations, enable adjustment for confounding, and improve capture of health outcomes. When creating such novel linked datasets, researchers should consider their suitability to meet research objectives, assess source data completeness and population coverage, and ensure well-defined data governance standards and protections exist. Additionally, while the RECORD-PE guidelines assist in the reporting of studies using observational health data specific to pharmacoepidemiology, they do not address the unique requirements for transparent evaluation and reporting of the data linkage process. Objectives and Approach We aimed to 1) provide guidance on data linkage appropriateness and feasibility to plan purposeful and sustainable new linkages that advance pharmacoepidemiological research and 2) generate a checklist with specific recommendations to assist researchers in providing clear and transparent assessment of the linkage process. To develop these guidelines, a working group comprised of members of the International Society of harmacoepidemiology was formed. Recommendations were open for comment by Society members and endorsed by the Society. Results Guidance for feasibility assessment was categorized into five domains: (1) research objectives and justification; (2) data quality and completeness; (3) the linkage process; (4) data ownership and governance; and (5) overall value added by linkage. A checklist for evaluation and reporting of data-linkage processes covered five domains including; (1) data sources; (2) linkage variables; (3) linkage methods; (4) linkage results; and (5) linkage evaluation, including validation and verification of the resulting linked data. Conclusion/Implications Our guidelines for data linkage feasibility assessment and reporting can be used to inform the design of sustainable linked data resources and for transparent communication of linkage processes. Together, these guidelines will help various stakeholders to critically assess the potential for bias in research based on linked data and help generate actionable evidence.
url https://ijpds.org/article/view/1572
work_keys_str_mv AT nicolepratt guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
AT daniellechun guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
AT kourtneydavis guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
AT bradhammill guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
AT christianhampp guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
AT christinamack guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
AT annemariemeyer guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
AT sudharaman guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
AT donnarivera guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
AT sokosetoguchi guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
AT tilsturmer guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
AT jenniferlund guidelinesfordatalinkageinpharmacoepidemiologyassessingfeasibilityevaluatingqualityandtransparentreporting
_version_ 1724275202766929920